Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial

Published:2014-11 Issue:12 Volume:15 Page:1379-1388
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ellis Peter M,Shepherd Frances A,Millward Michael,Perrone Francesco,Seymour Lesley,Liu Geoffrey,Sun Sophie,Cho Byoung Chul,Morabito Alessandro,Leighl Natasha B,Stockler Martin R,Lee Christopher W,Wierzbicki Rafal,Cohen Victor,Blais Normand,Sangha Randeep S,Favaretto Adolfo G,Kang Jin Hyoung,Tsao Ming-Sound,Wilson Carolyn F,Goldberg Zelanna,Ding Keyue,Goss Glenwood D,Bradbury Penelope Ann

Funder

Canadian Cancer Society Research Institute to the NCIC Clinical Trials Group

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Cancer facts & figures,2010

2. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J Clin Oncol,2008

3. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

4. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

5. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study;Cappuzzo;Lancet Oncol,2010

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis;Targeted Oncology;2024-06-01

2. Use of conditional estimates of effect in cancer epidemiology: An application to lung cancer treatment;Cancer Epidemiology;2024-02

3. Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study;ESMO Open;2023-12

4. Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma;Investigational New Drugs;2023-06-16

5. Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes;BMC Medicine;2023-02-24